Both doses of the vaccine are also highly effective against the new variant B 1.617.2 of the corona virus, which first appeared in India. A recent study by the Department of Health in the UK revealed this information. Public Health England (PHE) said on Saturday that both doses of the Pfizer-BioNotech vaccine were 88 percent and the Oxford-AstraZeneca vaccine 60 percent effective against the B1.617.2 variant of the corona virus.
In the UK, this variant is categorized as Variant of Concern (VOC). However, according to the study, only one dose of a vaccine is only 33 percent effective against this variant. In India, the Serum Institute of India is making AstraZeneca’s vaccine under the name Covishield.
Britain’s Health Minister Matt Hancock said, “This new fact is important and proves how valuable the vaccination campaign launched to protect its odd people from the Corona epidemic.”
He said that the study also proves how important the second dose of vaccine is to protect against the corona virus. Therefore, it is urged to all people to have both doses of the vaccine. The study found that both doses of the vaccine are nearly as effective against the B1.617.2 variant, as against the B1.1.7 variant first encountered in Kent, UK.
